Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, will present Sareum’s cancer drug discovery pipeline at BIO-Europe 2009 later today.

BIO-Europe, being held this year in Vienna, Austria, is Europe’s largest biotechnology partnering event. Dr Mitchell’s presentation is part of the UK Showcase, an International Seminar introduced by UK Trade & Investment.

Sareum Holdings plc
Tim Mitchell	01223 497 700

Merchant John East Securities Limited
Simon Clements/Bidhi Bhoma	020 7628 2200

Hybridan LLP
Claire Noyce/Stephen Austin	020 3159 5085

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.

Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk